DiObex is a biopharmaceutical company that has one of the lead compounds for the treatment of type 2 diabetes via the innovative cortisol pathway in clinical testing. This new mechanism of action might also lead to the prevention of metabolic syndrome. Their pipeline includes products targeted at significant unmet medical needs in metabolic disorders including type 1 diabetes, dyslipidemia, obesity, and diabetic nephropathy.
Martin Welschof, Opsona:
"Inventages had the vision and courage to support Opsona's quest to develop first in class and revolutionary treatment option targeting key structures of the innate immune system." More...
"Inventages had the vision and courage to support Opsona's quest to develop first in class and revolutionary treatment option targeting key structures of the innate immune system." More...